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Abstract 
Axon growth is coordinated by multiple interacting proteins that remain incompletely characterized. 
High content screening (HCS), in which manipulation of candidate genes is combined with rapid image 
analysis of phenotypic effects, has emerged as a powerful technique to identify key regulators of axon 
outgrowth. Here we explore the utility of a genome editing approach referred to as CRISPR (Clustered 
Regularly Interspersed Palindromic Repeats) for knockout screening in primary neurons. In the CRISPR 
approach a DNA-cleaving Cas enzyme is guided to genomic target sequences by user-created guide 
RNA (sgRNA), where it initiates a double-stranded break that ultimately results in frameshift mutation 
and loss of protein production. Using electroporation of plasmid DNA that co-expresses Cas9 enzyme 
and sgRNA, we first verified the ability of CRISPR targeting to achieve protein-level knockdown in 
cultured postnatal cortical neurons. Targeted proteins included NeuN (RbFox3) and PTEN, a well-
studied regulator of axon growth. Effective knockdown lagged at least four days behind transfection, 
but targeted proteins were eventually undetectable by immunohistochemistry in > 80% of transfected 
cells. Consistent with this, anti-PTEN sgRNA produced no changes in neurite outgrowth when assessed 
three days post-transfection. When week-long cultures were replated, however, PTEN knockdown 
consistently increased neurite lengths. These CRISPR-mediated PTEN effects were achieved using 
multi-well transfection and automated phenotypic analysis, indicating the suitability of PTEN as a 
positive control for future CRISPR-based screening efforts. Combined, these data establish an example 
of CRISPR-mediated protein knockdown in primary cortical neurons and its compatibility with HCS 
workflows. 
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1. Introduction 
The growth of axons and dendrites depends on numerous cellular processes including cytoskeletal 
remodeling, membrane expansion, intracellular signaling, regulated transport, and transcription. Thus, 
the coordinated activity of hundreds of proteins is needed for effective neurite extension. Identifying 
the full set of proteins that regulate axon growth remains a key objective in regenerative neuroscience 
and is critical for ongoing efforts to improve regenerative ability in neurons that have lost axons to 
injury or disease. For instance, it is now clear that targeted manipulation of gene expression in injured 
neurons is an effective means to improve axon growth (Belin et al., 2015, Blackmore et al., 2012, Sun 
et al., 2011, Wang et al., 2015). Improvements remain partial, however, motivating the search for 
additional regulatory proteins that might act as therapeutic targets. 
Forward genetic screens performed in primary neurons have emerged as a powerful tool to discover 
novel regulators of neurite growth (Blackmore, 2012). These screens generally rely on two 
components. First, approaches such as electroporation or viral transduction in multi-well format are 
used to achieve high throughput genetic modification of primary neurons. Second, automated image 
analysis in multi-well format rapidly quantifies effects on neurite extension. This readout can be 
performed on the overall population of neurons (e.g. “well-based” quantification), or can assess 
neurite length from individual neurons (e.g. “cell-based” analysis). A variety of labs have now 
harnessed this genetic screening approach, leading to a rapid expansion of the set of known regulators 
of axon growth (Blackmore, 2012, Blackmore et al., 2010, Buchser et al., 2012, Simpson et al., 2015, 
Zou et al., 2015). Many of these screens involve gene overexpression and thus address the sufficiency 
of ectopic gene expression to evoke phenotypic responses. To clarify the role of endogenous protein in 
neurite outgrowth, however, knockout approaches are necessary (e.g. Zou et al., 2015). 
Genome editing methods such as zinc finger nucleases (ZFNs), Transcription Activator-Like Effector 
Nucleases (TALENs), and Clustered Regularly Inter-Spaced Palindromic Repeats (CRISPR) represent 
potentially improved tools for knockout screening. Unlike previous RNAi approaches, which act post-
transcriptionally and may induce only partial protein knockdown, genome editing can modify DNA at 
specific loci to abolish protein production completely and permanently. CRISPR in particular has been 
widely adopted. CRISPR evolved as a bacterial adaptive immune system in which Cas (CRISPR-
associated) nucleases are directed to degrade foreign DNA (Kunin et al., 2007). DNA binding by Cas 
nucleases is limited to sequences adjacent to a specific 3-nucleotide protospacer adjacent motif (PAM) 
(Terns and Terns, 2011). Critically, Cas nucleases are guided to specific PAM-adjacent regions by RNAs 
that are complementary to the target DNA sequence. It is now well established that Cas proteins are 
functional when expressed in mammalian cells and can be directed to specific loci by supplying RNA 
sequences called single-guide (sgRNA) that contain a user-designed targeting domain. Cas nucleases 
initiate double-stranded breaks followed by error prone non-homologous end-joining (NHEJ), resulting 
in insertion or deletion mutations that disrupt the production of functional protein when directed to 
coding regions. Importantly, examples now exist to demonstrate the efficacy of protein-level knockout 
by the CRISPR strategy in neurons (Platt et al., 2014, Straub et al., 2014, Swiech et al., 2015, 
Zuckermann et al., 2015). 
There may be unique challenges, however, to adopting the CRISPR approach to screening in post-
mitotic neurons. First, previous CRISPR-based screens in non-neuronal cells have relied on purifying 
and expanding affected cells with antibiotic resistance genes or fluorescent reporters to obtain 
knockout clones (An et al., 2014, Chen et al., 2015, Schmid-Burgk et al., 2016, Wang et al., 2014). 
Without the option of proliferation-based purification, however, gene delivery methods for neurons 
must be rapid and efficient. Second, no studies have yet determined how quickly CRISPR causes 
knockdown in neurons. There must be a defined timecourse of knockdown in order to rationally plan 
experimental endpoints. Finally, the few publications that have utilized CRISPR in cultured neurons 
have used lentiviral-based approaches to force expression of a Cas enzyme and an sgRNA (Incontro et 
al., 2014, Telese et al., 2015). Large-scale screening, however, may be more feasible and economical 
using plasmid-based transfection (Ebert et al., 2008, Moffat et al., 2006, Root et al., 2006). 
Here we performed validation and optimization experiments to assess the utility of CRISPR for high 
content screening in neurons. Using delivery of Cas9 and sgRNA by plasmid electroporation in multi-
well format, we first confirmed the timecourse of protein knockdown using a previously validated 
targeting sequence for NeuN (Rbfox3), a ubiquitously expressed neuronal protein (Platt et al., 2014). 
We next designed and delivered sgRNA against Phosphatase and Tensin homolog (PTEN), a well-
studied inhibitor of neurite outgrowth. For both targets the majority of neurons were unaffected by 
CRISPR knockdown until 4 to 6 days post-transfection and during this time they extended lengthy 
processes that were not amenable to neurite outgrowth analysis. Therefore, we developed a replating 
approach to disentangle overgrown neurites. Following replating automated microscopy was able to 
detect a robust outgrowth phenotype from PTEN knockout, thereby establishing a positive control for 
CRISPR-based phenotypic screening. 
2. Methods 
2.1. Cloning and plasmid preparation 
pX330-U6-Chimeric_BB-CBh-hSpCas9 was a gift from Feng Zhang (Addgene plasmid # 42230). The 
targeting sequence for NeuN was taken from Platt et al. (2014). Targeting sequences for PTEN were 
designed using the publicly available Benchling CRISPR design tool (http://www.benchling.com). The 
overhang ‘CACC’ was added to the 5′ end of the two sgRNA sequences with the highest on-target score 
and the overhang ‘CAAA’ was added to the 5′ end of the reverse complements of these sequences. 
Anti PTEN sequences were GGTGGGTTATGGTCTTCAAA (PTEN A), TTTCCTGCAGAAAGACTTGA (PTEN B), 
CACCGGTTTGATAAGTTCTAGCTG (PTEN C), and CACCGTTTGTGGTCTGCCAGCTAA (PTEN D). The anti-
NeuN sequence was CAGCAGCCCAAACGACTACAT, and the non-targeting control sequence was 
GGGTCTTCGAGAAGACCTGT. Oligonucleotides of the targeting sequences and reverse complements 
with overhangs were ordered from ThermoFisher and annealed. Bbs1 enzyme was used to digest the 
PX330 plasmid and the annealed oligonucleotides were ligated into the cut backbone using T4 ligase as 
described in Cong et al. (2013). The PX330 plasmid containing sgRNA targeting sequences were then 
transformed into E. cloni Chemically Competent Cells (VWR 95040-456) and DNA was prepared by 
QIAprep Spin Miniprep Kit (Qiagen 27,106). The reporter plasmid expressed EBFP-2A-H2B-EGFP from a 
CMV promoter, and was constructed by replacing the 2A-mCherry sequence from a reporter previously 
described in Wang et al. (2015) with EGFP fused to H2B to drive nuclear localization. 
2.2. Cortical cell dissociation, transfection, and culture 
All animal procedures were approved by the Marquette University Institutional Animal Care and Use 
Committee. Cortical neurons were prepared from early postnatal (P3–P5) Sprague Dawley rat pups 
(Charles River) and transfected as in Blackmore et al. (2010). Frontal cortices were placed in ice-cold 
Hibernate E (Life Technologies A12476-01), their meninges removed, finely minced and transferred 
into 10 ml dissociation media for 30 min at 37 °C with constant shaking (Hibernate E containing 
20 U/ml papain (Worthington 3126) and 2.5 μg/ml DNAse (Sigma D4527)). Cells were then rinsed with 
Hibernate E + 2% SM1, then rinsed in Hibernate E (no SM1), and incubated 30 min at 37 °C with 
constant shaking in 10 ml trypsin solution (Hibernate E containing 0.25% trypsin (Invitrogen/Gibco 
15,090–046) and 2.5 μg/ml DNAse (Sigma D4527)). Cells were centrifuged (1 min, 10 g), washed with 
Hibernate E + 2% SM1, and triturated three times in 1.5 ml Hibernate E + 2% SM1 containing 2 μl 
DNAse (Sigma D4527). The suspension was allowed to settle for 2 min and the supernatant was 
collected; these steps were repeated until no cell pellet was visible. This process typically yielded 
2 million cells/ml in 6–7 ml Hibernate E. For transfection, cortical neurons were centrifuged (4 min, 
80 g) and resuspended to 2 × 106 cells/ml in Internal Neuronal Buffer (INB) (KCl 135 mM, CaCl2 
0.2 mM, MgCl2 2 mM, HEPES 10 mM, EGTA 5 mM, pH 7.3). 25 μl were placed into wells of a 96-well 
electroporation plate (BTX Harvard Apparatus 45–0450) and mixed with 25 μl of INB containing 1 μg 
EGFP plasmid and 4 μg test plasmid. A 350 V, 300 μs pulse was delivered to each well by an ECM 
square wave pulse generator (Harvard Apparatus ECM-830) attached to a plate handler (BTX Harvard 
Apparatus HT-200). After electroporation each well received 100 μl of Hibernate E. For short-term cell 
culture experiments, 10,000 cells/well, or for long-term cell culture experiments 100,000 cells/well, 
were placed in 24-well plates (Greiner Bio-One 662,160) pre-coated with 100 μg/ml poly-d-lysine 
hydrobromide (Sigma P7886) (N12 h, 37 °C), followed by 10 μg/ml laminin (Sigma L2020) (N2 h, 37 °C). 
Cells were maintained at 37 °C, 5% CO2 in Enriched Neurobasal (ENB) media, modified from Meyer-
Franke et al. (1995), consisting of Neurobasal A (Invitrogen 10,888–022), 50X NeuronCult SM1 
Neuronal Supplement (Stemcell Technologies 5711), 1 mM sodium pyruvate (Invitrogen 11,360-070), 
2 mM GlutaMAX (Invitrogen/Gibco 35,050-061), 50 U/ml penicillin–streptomycin (Invitrogen 15,070-
063), 5 μM forskolin (Sigma F6886), 
To enrich for neurons in cultures maintained for longer than 3 days, 100 nM 5-fluoro-2′-deoxyuridine 
(FuDR) (Sigma-Aldrich F0503) was added to each well 1 day post-transfection. To facilitate long-term 
survival the media was replaced every 3 days, with fresh cortical media in the replating experiments 
and with FuDR-containing media in the time course experiments. 
2.3. Cortical cell culture replating 
Primary cortical neurons were transfected and cultured as previously described (Blackmore et al., 
2010). Wells were rinsed twice with 400 μl of Hibernate E and then incubated for 10 min at 37 °C in 
400 μl of StemPro Accutase Cell Dissociation Reagent (ThermoFisher A1110501). Accutase was then 
diluted with 400 μl of fresh cortical media, cells were detached by pipetting three times, with half the 
well volume aspirated and dispensed each time. Dissociated cells collected by centrifugation (4 min, 
80G). Cells were resuspended in 1 ml, counted, and plated at 10,000/well in 24-well plates (Greiner 
Bio-One 662,160) pre-coated with PDL/laminin using conditioned media from the original plate. 
Replated cells were fixed after 24 h in 4% PFA. 
2.4. Cortical cell culture immunohistochemistry 
Cultures were fixed in 4% paraformaldehyde (Electron Microscopy Sciences 15,710) for 30 min at room 
temperature, rinsed five times, blocked and permeabilized (PBS, 20% goat serum (Invitrogen 16,210-
064), 0.2% Triton X-100 (G-Biosciences 786-513) for 30 min at room temperature, and incubated in 
primary antibody solution (PBS, 10% goat serum, 0.2% Triton X-100, primary antibodies: rabbit anti-
βIIItubulin (1:500, Sigma T2200), mouse anti-NeuN (1:500, Millipore MAB377), rabbit anti-PTEN (1:500, 
Cell Signaling 138G6) (overnight, 4 °C). After five washes, cultures were incubated in secondary 
antibody solution containing DAPI nuclear stain (PBS, 10% goat serum, 0.2% Triton X-100, 300 nM 
DAPI, dilactate (molecular probes D3571) secondary antibodies: Alexa Fluor 647 goat anti-rabbit IgG 
(1:500, Invitrogen A-21245), Alexa Fluor 546 goat anti-mouse IgG (1:500, Invitrogen A-11003)) for 2 h 
at room temperature. Plates were washed five times, and left in 1 ml PBS for imaging. 
2.5. Quantification of immunofluorescence 
For the time course of PTEN knockdown experiments, a fluorescent inverted microscope was used to 
identify EGFP + NeuN + cells as transfected neurons. For the time course of NeuN knockdown 
experiments, a fluorescent inverted microscope was used to identify EGFP + ΒIII-tubulin + cells as 
transfected neurons. A circle was drawn around the cell body of each transfected cell and the 
fluorescence level of either NeuN or PTEN staining was recorded as quantified by NIS-Elements Basic 
Research software. For all treatments and time points n = 40 transfected cells. Statistical analysis was 
paired t-test using Graphpad Prism Software. 
2.6. Neurite outgrowth analysis 
For neurite outgrowth assays, Cellomics Cell Insight NXT (Thermo Scientific) acquired images of 3 
channels: nuclei (DAPI), neurite staining (βIII-tubulin), and reporter (EGFP), and Cellomics Scan v6.4.0 
(Thermo Scientific) traced neurites and quantified reporter intensity. Average total neurite length was 
quantified for the 10% of cells with greatest EGFP intensity per plate (n > 100 cells per treatment). 
Average neurite length was normalized to PX330 non-target control for each plate. Each treatment was 
tested at least three times. Statistical analysis was paired t-test using Graphpad Prism Software. 
3. Results 
3.1. Time course of CRISPR-mediated knockout of target proteins in primary 
cortical neurons 
CRISPR has been extensively used to decrease protein expression in mitotically active cells and 
recently, knockdown in post-mitotic neurons has been achieved. For example, an sgRNA targeting 
sequence against neuron-specific NeuN was shown to reduce NeuN protein expression in adult cortical 
neurons in vivo upon transgenic co-expression of spCas9 (Platt et al., 2014). We therefore asked 
whether this same targeting sequence affected NeuN expression in primary cortical neurons that were 
transfected to express spCas9 and, if so, over what time course. The validated anti-NeuN targeting 
sequence was cloned into the Px330 plasmid, which co-expresses spCas9 and sgRNA (Cong et al., 
2013). Using previously established techniques, plasmid was then delivered by electroporation to 
cortical neurons prepared from postnatal (P3–P5) rat pups (Blackmore et al., 2010, Buchser et al., 
2006). To identify transfected cells, an EGFP reporter was co-transfected at a 1:4 ratio, a strategy 
shown previously to result in > 90% co-expression of test plasmid and reporter (Blackmore et al., 
2010). Neurons were plated at high density (100,000 cells plated per well in 24-well format) in media 
containing 5-Fluoro-2′-deoxyuridine (FuDR) to limit glial proliferation, and then fixed every two days 
between 4 and 14 days in vitro (DIV). Then, NeuN immunofluorescence was quantified in transfected 
neurons, which were identified by EGFP and immunohistochemistry for neuron-specific ΒIII-tubulin 
(Fig. 1A–C). After 4 days, a significant but modest decrease in average NeuN immunofluorescence was 
detected in anti-NeuN treated cells compared to control cells transfected with SpCas9 and non-
targeted sgRNA (Fig. 1D). Importantly, only 20% of anti-NeuN treated cells showed NeuN levels that fell 
below a threshold set by the dimmest 5% of control cells. Two days later, however, anti-NeuN 
displayed a larger reduction in average NeuN immunofluorescence, and > 50% of transfected cells 
were dimmer than the lowest 5% of control cells. Later time points showed a trend toward lower NeuN 
expression, with > 75% of transfected cells dimmer than 95% of control cells (Fig. 1D). These data 
confirm that CRISPR-mediated knockout of NeuN is effective in cultures of primary cortical neurons, 
but requires approximately a week to strongly affect a majority of transfected neurons. 
  
Fig. 1. CRISPR effectively decreases NeuN protein levels in primary neurons. P3–P5 cortical neurons were 
transfected with plasmid DNA co-expressing spCas9 and anti-NeuN or non-targeted sgRNA. Neurons were 
cultured, fixed between 4 and 14 days in vitro (DIV), and immunostained for neuron-specific βIII tubulin and 
NeuN. (A–C) show anti-NeuN treated neurons 14 days after transfection. EGFP (B) identifies transfection 
(arrow). (C) Immunohistochemistry detects NeuN protein in a EGFP-negative neuron (arrowhead), but not in a 
transfected neighbor (arrow). (D) Each dot represents NeuN immunofluorescence intensity in a single 
transfected (EGFP +) neuron between 4DIV and 14DIV. Grey boxes indicate a threshold set by the dimmest 5% of 
control-transfected neurons at each timepoint, and the percent of anti-NeuN cells that fall below that threshold 
is quantified above. Significant differences existed between the population-level average intensity at all 
timepoints (p = 0.033 4DIV, p = 7.4 × 10− 9 6DIV, p = 1.8 × 10− 8 8DIV, p = 3.7 × 10− 5 10DIV, p = 1.6 × 10− 7 12DIV, 
p = 7.9 × 10− 12 14DIV; unpaired t-test), and the percent of anti-NeuN cells below threshold increases between 4 
and 6DIV. N = 40 cells per group per timepoint. 
We next sought to determine the efficacy and time course of CRISPR-based knockout of a second 
protein, which had not previously been targeted with a CRISPR approach. We selected PTEN for 
knockdown based on its well-established role in neurite outgrowth in other types of neurons (reviewed 
in Ohtake et al., 2015). Using publicly available algorithms to maximize selectivity and efficacy (Doench 
et al., 2014, Hsu et al., 2013), short oligonucleotides containing anti-PTEN targeting sequences were 
synthesized, annealed, and ligated into the PX330 plasmid (Cong et al., 2013). As before, P3–P5 rat 
cortical neurons were electroporated with 4 μg of anti-PTEN or control PX330 plasmid and plated in 
FuDR-treated media, then fixed every 2 days starting at 4DIV and ending at 14DIV. Neurons were 
identified by immunohistochemistry for NeuN and transfected cells were identified by the expression 
of EGFP (Fig. 2A–C). PTEN expression was manually quantified by drawing a region of interest around 
the cell body of transfected neurons and recording average PTEN immunofluorescence, as measured 
by NIS-elements software. Four days after transfection, average PTEN fluorescence was significantly 
reduced in the anti-PTEN group, and 67% of transfected neurons fell below the dimmest 5% of control 
neurons. Two days later, average PTEN fluorescence was further reduced in the anti-PTEN group, and 
85% of neurons fell below the 5% threshold (Fig. 2D). Thus, user-designed CRISPR targeting sequences 
effectively decreases protein expression of PTEN in primary cortical neuron cultures on a time scale of 
four to six days. 
 
 
Fig. 2. CRISPR effectively decreases PTEN protein levels in primary neurons. P3–P5 cortical neurons were 
transfected with plasmid DNA co-expressing spCas9 and anti-PTEN or non-targeted sgRNA. (A–C) show neurons, 
identified by NeuN (A), 14 days after transfection with anti-PTEN. (B) EGFP identifies transfection (arrow). (C) 
Immunohistochemistry detects PTEN protein in a EGFP-negative neuron (arrowhead), but not in a transfected 
neighbor. (D) Each dot represents PTEN immunofluorescence intensity in a single transfected (EGFP +) neuron 
between 4DIV and 14DIV. Grey boxes indicate a threshold set by the dimmest 5% of control-transfected neurons 
at each timepoint, and the percent of anti-PTEN cells that fall below that threshold is quantified above. 
Significant differences existed between the population-level average intensity at all timepoints (p = 6.9 × 10− 11 
4DIV, p = 1.4 × 10− 8 6DIV, p = 5.0 × 10− 13 8DIV, p = 3.3 × 10− 15 10DIV, p = 4.8 × 10− 14 12DIV, p = 3.7 × 10− 17 14DIV; 
unpaired t-test), and by 6DIV 85% of anti-PTEN treated cells fell below the 5% threshold. N = 40 cells per group 
per timepoint. 
One potential strategy to accelerate protein knockdown may be to use multiple sgRNAs that target 
discrete coding regions of the same gene. To test this possibility, four sgRNA sequences against PTEN 
were designed and delivered singly or in pair-wise combinations to early postnatal cortical neurons. In 
order to facilitate comparison with established shRNA-based approaches, cells were transfected with 
anti-PTEN shRNA shown previously to be effective in CNS neurons (Yungher et al., 2015). Cells were 
maintained between 2 and 14 days in culture, fixed, and visualized with immunohistochemistry against 
PTEN and neuron-specific βIII tubulin. In contrast to the manual quantification performed above, in this 
experiment we utilized a Cellomics high content screening microscope to assess PTEN intensity, which 
enabled analysis of hundreds of cells per treatment at each timepoint. In this analysis, the 10% of cells 
with the brightest EGFP signal were quantified, in order to focus the analysis on effectively transfected 
neurons. In support of this, we found that reduction in PTEN expression was greatest in the top 10% of 
EGFP-expressing cells (Supplementary Fig. 1). As shown in Fig. 3, all four anti-PTEN sgRNA sequences 
produced significant knockdown of PTEN in transfected neurons. Consistent with the previous manual 
quantification, the percent of neurons with PTEN intensity below the 5% control threshold increased 
from 8 to 10% at 2DIV to 51–66% at 14DIV. Mixtures of two sgRNAs did not accelerate the onset of 
knockdown or increase the percent of affected cells at later timepoints. Interestingly, knockdown of 
PTEN protein via shRNA was much more rapid, with 58% of cells below the 5% threshold after only 
2DIV. Overall, these data confirm a lag in the onset of protein knockdown by Cas9 compared to shRNA. 
Moreover, combined sgRNA sequences did not shorten this lag. 
Fig. 3. Four distinct anti-PTEN CRISPR constructs display similar timecourse of protein knockdown, which is 
delayed compared to shRNA-mediated knockdown. P3–P5 cortical neurons were co-transfected with EGFP 
reporter and plasmid co-expressing spCas9 and one of four distinct sgRNA sequences targeting PTEN, or 
mixtures of two sequences. In parallel, neurons were also transfected with anti-PTEN shRNA. Between 2 and 
14 days later, cells were fixed and immunostained for PTEN protein, and Cellomics automated microscopy was 
used to quantify immunofluorescence in EGFP + cells. (A) shows example histograms comparing PTEN 
immunofluorescence in populations of neurons transfected with anti-PTEN sgRNA and non-targeting control. At 
two days post-transfection the populations mostly overlap, but in subsequent days the percent of cells with low 
PTEN expression increases in the sgRNA treatment. Vertical lines indicate a threshold of PTEN signal set by the 
dimmest 5% of control cells. (B) quantifies the percent of EGFP + cells with PTEN intensity below a the 5% 
threshold at the same timepoint. At two days post-transfection, single and mixed sgRNA-treated populations 
display only 5% of cells below this threshold, while > 50% of shRNA-treated cells fall below threshold. By six 
days, between 40 and 50% of sgRNA-treated cells fall below threshold. More than 500 cells were analyzed in 
each treatment at each timepoint. 
3.2. Functional testing CRISPR-mediated phenotype in an HCS workflow 
Having established effective CRISPR-mediated protein reduction in primary neurons, we next asked 
whether this approach could yield reproducible effects on neurite outgrowth using approaches 
compatible with HCS screening. Previous screens have utilized plasmid electroporation and culture in 
multi-well format, followed by automated image acquisition and quantification of neurite outgrowth 
with Cellomics instrumentation (Blackmore et al., 2010, Simpson et al., 2015). This endpoint analysis is 
typically performed no more than three days in culture, after which time extensive overlap of neurites 
makes cell-based quantification very difficult. Although the previous timecourse data suggested it  
might be unlikely that phenotypic effects of CRISPR-mediated knockdown would be detectable within 
three days of transfection, we nevertheless tested the effects of anti-PTEN sgRNA using this lab 
standard protocol. As before, P4 cortical neurons were transfected with PX330-based plasmids 
encoding spCas9 and non-target, anti-PTEN, or anti-NeuN sgRNA as well as an EGFP reporter at a 1:4 
ratio. Neurons were then cultured on PDL/laminin substrate for three days, fixed and stained with 
neuron-specific ΒIII tubulin, and neurite lengths quantified in transfected neurons. As shown in Fig. 4, 
neurite length in cells transfected with anti-PTEN sgRNA did not differ significantly from anti-NeuN or 
non-target controls. 
Fig. 4. Short-term treatment with anti-PTEN CRISPR does not affect neurite length in primary cortical neurons. 
P3–P5 cortical neurons were transfected with plasmid DNA co-expressing spCas9, anti-NeuN, anti-PTEN or non-
targeting sgRNA, along with plasmid encoding EGFP reporter. (A–I) Example images from ThermoScientific 
Cellomics CX5 high content screening platform. Neurons are identified by βIII-tubulin (A, D, G) transfection by 
EGFP (arrows, B, E, H), and neurite are traced (C, F, I) using βIII-tubulin fluorescence (J) Quantification of total 
neurite length shows no significant differences between any groups (p > 0.05, matched pair t-test with 
Bonferonni's correction). N > 100 cells per group in three replicate experiments. 
One possible explanation for these negative results is that during the first three days post-transfection 
the degree of protein reduction was insufficient to affect neurite lengths. To test this possibility we 
adopted a strategy of maintaining longer term, high-density cultures, followed by replating. As before, 
P3–5 cortical neurons were transfected in multi-well format, but were plated and maintained at a 
relatively high density (100,000 cells plated per well in 24-well format) for seven days. As a positive 
control, additional cells were transfected with plasmid to overexpress Jun, shown previously to 
enhance neurite outgrowth in this cell type (Lerch et al., 2014, Simpson et al., 2015). FuDR was added 
to the media to block glial proliferation, resulting in > 95% pure neuronal cultures. After seven days, 
neurons were dissociated with Accutase and replated at a density of 10,000 cells per well on 
PDL/laminin substrates. After 24 h of neurite extension the replated neurons were fixed, stained with 
ΒIII tubulin, and analyzed with Cellomics instrumentation as above (Fig. 5A–I). Although this procedure 
resulted in significant cell death, several hundred transfected neurons survived and extended neurites 
that were readily quantified. JUN overexpression enhanced neurite outgrowth by an average of 33.5% 
(± 12.8% SEM) across three replicate experiments, similar to the 26.2% (± 6.9% SEM) seen in previous 
short-term screening experiments (Fig. 5J) (Simpson et al., 2015). These data confirm the sensitivity of 
this replating approach for detection of known growth phenotypes. In replated neurons treated with 
anti-PTEN sgRNA, neurite lengths were significantly elevated compared to non-targeted controls across 
four replicate experiments (136.8 ± 8.0% SEM, p < 0.01, ANOVA with post-hoc Dunnett's) (Fig. 5J). 
Immunohistochemistry for PTEN protein in the replated neurons confirmed effective knockdown, as 
75% of cells fell below the threshold set by the dimmest 5% of control neurons (Supplementary Fig. 2). 
These data indicate that reduction of PTEN expression in early postnatal cortical neurons results in 
increased neurite lengths. 
  
Fig. 5. CRISPR-mediated knockdown of PTEN increases neurite length at a 7DIV timepoint. P3–P5 cortical 
neurons were transfected with plasmid DNA expressing Jun or spCas9 and sgRNA (anti-PTEN or non-targeting 
sgRNA), along with plasmid EGFP reporter. (A–I) show example images from ThermoScientific Cellomics CX5 high 
content screening platform. The automated microscope identifies neurons by βIII-tubulin (A, D, G) and 
transfection by EGFP (arrows) (B, E, H). CellInsight Cell Analysis software then automatically traces neurites (C, F, 
I) using the βIII-tubulin fluorescence. Compared to non-targeted sgRNA control (A, B, C,), increases in neurite 
length of transfected cells are apparent after Jun overexpression (D, E, F) or PTEN knockout (G, H, I). (J) 
Quantification of total neurite length shows significant increases in neurons treated with Jun overexpression and 
anti-PTEN sgRNA (p < 0.05, matched pair t-test with Bonferonni's correction). N ≥ 100 cells in 3 experimental 
replicates. (K) In a separate experiment, neurons were transfected with four distinct anti-PTEN sgRNA 
sequences, or pairwise combinations, maintained 7DIV, and then replated. 24 h later, Cellomics-based 
quantification showed that three constructs caused significant increases in total neurite length, and the fourth 
showed a similar trend. p < 0.05, ANOVA with post-hoc Dunnett's, N > 500 cells per treatment. 
It is possible that increased neurite outgrowth produced by treatment with anti-PTEN CRISPR 
sequences could result from off-target effects. Although off-target mutations can be detected through 
approaches like next-generation sequencing, a more practical solution in a screening experiment is to 
employ multiple targeting sequences against distinct regions of the same gene. Because different 
sgRNA constructs are unlikely to affect common off-target sequences, consistency of the evoked 
phenotype increases confidence that on-target knockdown explains the observed effects. Indeed, we 
found that three of the four validated anti-PTEN sgRNA sequences significantly increased neurite 
length compared to non-specific sgRNA (p < 0.05, ANOVA with post-hoc Dunnett's), and the forth 
sequence displaying a similar trend (Fig. 5K). Thus it is most likely that CRISPR-mediated knockdown of 
PTEN protein, as opposed to off-target effects, was responsible for the increased neurite length. 
Importantly, these data also provide positive control sequences for CRISPR-mediated effects on neurite 
outgrowth, laying critical groundwork for the establishment of CRISPR-based screening approaches in 
primary neurons. 
4. Discussion 
We have assessed the suitability of CRISPR-based genome editing for use in phenotypic screening in 
primary neurons. Using cultured cortical neurons, we have established the time course and efficacy of 
CRISPR knock down for two proteins, NeuN and PTEN. We also established a replating technique for 
postnatal cortical neurons in order to assay neurite outgrowth when an extended period in culture is 
required. Finally, we show that CRISPR-based knockout of PTEN, delivered by electroporation in 
multiwell format, causes an increase in neurite outgrowth that is readily detectable by an automated 
screening platform. Overall, these results demonstrate the feasibility of performing a CRISPR-based 
high content knockout screen. 
4.1. The role of PTEN in early postnatal neurite outgrowth 
PTEN, an upstream inhibitor of PI3K signaling and the mTOR pathway, was selected for this validation 
study because it has been shown to act in a variety of cell types as a negative regulator of axon 
extension. For example, transgenic knockout and shRNA-mediated knockdown of PTEN cause 
increased regenerative axon growth in retinal ganglion cells (Park et al., 2008, Yungher et al., 2015), 
corticospinal tract neurons (Liu et al., 2010, Zukor et al., 2013), rubrospinal neurons (Geoffroy et al., 
2016), and dorsal root ganglion neurons (Christie et al., 2010). The timing of knockdown appears to 
affect the rate of axon extension triggered by PTEN ablation, with stronger regenerative responses 
observed when PTEN is pre-ablated early in postnatal development and injuries performed after 
maturation (Geoffroy et al., 2016). Indeed, despite the clear role for PTEN in limiting axon growth in 
adult CNS neurons, it was previously unclear whether PTEN is similarly inhibitory in the cellular context 
of immature neurons, which possess a higher innate growth ability and lower levels of endogenous 
PTEN. The current data clearly indicate that PTEN is present in cortical neurons during early postnatal 
periods, and that PTEN ablation increases total neurite extension. 
4.2. Challenges and unanswered questions 
An important question for any knockdown approach is the degree of specificity. In the case of CRISPR, 
knockout of off-target proteins by sgRNA could potentially produce phenotypic changes, leading to 
false positive screening results. Cleavage efficiency by CRISPR is strongly reduced by mismatches in the 
20 nt sgRNA/DNA binding site, particularly if multiple mismatches are located in PAM-proximal region 
(Hsu et al., 2013). Publically available algorithms now exist to scan genomes and identify sgRNA 
sequences with minimized potential for off-target cleavage; the sequences used here utilized the 
method of Hsu et al. (2013). Nevertheless, the potential remains for off-target DNA cleavage, and a 
variety of techniques have been developed in non-neuronal cells to detect them (reviewed in Wu et al., 
2014). For example, potential off-target sequences in the genome can be PCR-amplified and sequenced 
or analyzed by mismatch-specific nucleases (e.g. Surveyor). The most comprehensive approach is to 
perform whole genome sequencing of cell populations clonally derived from single sgRNA-treated cells 
(Smith et al., 2014, Veres et al., 2014). Genome-wide sequencing is likely not feasible in individual post-
mitotic neurons, and even PCR-based analysis of predicted off-target cleavage is likely impractical for 
most screening projects. Thus, the best safeguard against off-target, false-positive hits will likely be to 
test multiple sgRNA sequences against the same protein target, similar to the strategy adopted by 
previous RNAi screens (Nieland et al., 2014, Sharma et al., 2013, Welsbie et al., 2013). Importantly, our 
data indicate that in the case of PTEN knockdown, three of four sgRNA targeting sequences produced a 
significant increase in neurite length. Setting requirements for consistent phenotype across multiple 
targeting sequences greatly increases the probability that on-target effects are responsible. 
Several groups have shown that RNAi approaches can cause non-specific effects through an innate 
immune response resulting in the expression of interferon proteins (Bridge et al., 2003, Sledz et al., 
2003). Of particular relevance, lentiviral-mediated delivery of shRNA to primary neurons has been 
shown to elevate expression of interferon-stimulated genes such as Oas1, with attendant decreases in 
viability and neurite outgrowth (Bauer et al., 2009, Hutson et al., 2012). Incorporation of microRNA 
flanking sequences and designs that prevent the formation of perfect double stranded RNA helixes 
have been used to alleviate this interferon response (Bauer et al., 2009, Cullen, 2006). It is unknown 
whether Cas9 and sgRNA induce a similar response, although the single-stranded nature of the sgRNA 
may make it less likely. Nevertheless, in future work it will be critical to directly test for interferon 
responses and other potential non-specific effects of CRISPR in primary neurons. 
Another potential challenge is presented by the finding that CRISPR-mediated knockdown can take up 
to six days to affect the majority of transfected cells. After plasmid transfection, protein knockout can 
occur only after 1) production of Cas9 enzyme and sgRNA 2) Cas9-mediated cleavage at both genomic 
copies of PTEN and 3) clearance of existing protein pools. Which step contributes most to the six-day 
delay? We observe plasmid-driven expression of reporter proteins within 16 h of transfection, making 
it unlikely that delayed expression of Cas9 protein is a major culprit. Similarly, the half-life of PTEN has 
been estimated at about 7.5 h (Trotman et al., 2007), and using shRNA we observe knockdown that is 
strong at 2DIV and nearly complete by 4DIV (Fig. 3), consistent with previous use of this shRNA 
targeting sequence (Yungher et al., 2015). Thus, a slow rate of PTEN turnover is also unlikely to explain 
the delay. Combined, these observations suggest a model in which DNA cleavage by Cas9 is a 
stochastic event that affects an expanding fraction of the population over the course of several days. 
Expanded experimentation is needed to confirm that a six day lag to knockdown is a general feature of 
the CRISPR strategy in primary neurons. Nevertheless, it is notable that we observed very similar 
timecourses for five distinct sgRNAs against two protein targets. Thus potential users should be alert to 
the possibility that screens involving CRISPR manipulation of primary neurons may require 
approximately a week in culture to achieve protein knockdown in a majority of transfected cells, 
followed by additional time in culture for the phenotypic consequences to manifest. 
One consideration is that the timing of knockout may vary between individual cells (i.e. Cas9 cleavage 
may have affected some cells at 2DIV, others not until 6DIV). This range of time-since-knockout could 
act as a source of phenotypic variability. In addition, the lag between transfection and protein 
knockout may present a technical hurdle for some endpoint measurements, including screens of 
neurite outgrowth considered here. Indeed, we empirically tested and ruled out the possibility that 
CRISPR-based approach might be compatible with previous HCS workflows, in which neurite outgrowth 
was quantified at a 3DIV timepoint (Blackmore et al., 2010). We therefore adopted a replating 
technique, similar to procedures that we and others have used previously to disentangle dorsal root 
ganglion (DRG) neurons after extended culture (Simpson et al., 2015, Zou et al., 2009). This approach is 
feasible but introduces an extra step into the workflow and results in significant cell death, which 
increases the number of cells needed for the initial transfection step. In addition, the replating 
procedure likely introduces an increase in variability in subsequent neurite outgrowth, potentially 
reducing screen sensitivity. Indeed, when compared to prior data from non-replated neurons, we find 
a significant increase in variance of neurite length (standard deviation approximately 25% higher, F-test 
p < 0.01). Despite these caveats, however, this approach did produce consistent enhancement of 
neurite outgrowth after JUN overexpression and CRISPR-mediated PTEN knockout. The establishment 
of a consistent positive control is a promising step toward the use of CRISPR knockout in neurite 
outgrowth screens. 
Now that we have established positive controls it will be important to reduce variability and increase 
the sensitivity of future screens. One source of variability is imperfect co-transfection between 
separate Cas9 and EGFP plasmids, although our previous data predict a > 90% co-expression at the 1:4 
ratios used here (Blackmore et al., 2010). The PX330 vector we tested here does not include a reporter, 
and the large size of Cas9 creates challenges for reporter co-expression from a single plasmid. As a 
potential future solution, CRISPR technology allows for targeted homology-directed repair (HDR) (Cong 
et al., 2013). In this way a repair template containing either a fluorescent reporter or an antibiotic 
selection marker could be inserted when a target gene is nicked by Cas9. In principle, this approach 
would specifically identify cells affected by Cas9 enzyme. Challenges to this strategy include the fact 
that HDR has an extremely low efficiency, and the difficulty in distinguishing homozygous from 
heterozygous insertion, which could leave one copy of the target gene intact (Maruyama et al., 2015). 
Nevertheless, as CRISPR technologies rapidly evolve, HDR-based strategies may become more practical 
in a HCS environment. 
4.3. Future prospects for CRISPR-based screening in primary neurons 
One factor that may favor the adoption of CRISPR-based screening is the simplicity of creating effective 
reagents. In the current study, publically available algorithms were used to design targeting sequences 
ranked on the basis of specificity and efficacy. Following procedures described in Cong et al. (2013), 
short oligonucleotides were synthesized, annealed, and ligated into PX330 plasmid which co-expresses 
Cas9 and sgRNA. This process proved to be simple and highly economical; two features that make it 
portable to high content screens. This raises the prospect that large-scale, custom-designed CRISPR 
knockout libraries could be quickly and inexpensively created. 
A second potential advantage is the prospect of multiplex screening, e.g. simultaneous knockdown of 
multiple target genes. It has been shown that in the presence of multiple sgRNAs, Cas nucleases can 
cleave diverse DNA sequences in the same cell (Cong et al., 2013). This strategy has been used to 
achieve multiplex knockdown in a variety of systems, including zebrafish, mouse embryonic stem cells, 
human immortalized myoblasts, HEK293T cells, and yeast (Jakociunas et al., 2015, Jao et al., 2013, 
Kabadi et al., 2014, Ousterout et al., 2015, Yang et al., 2013). Notably, simultaneous knockdown of 
three proteins (DNMT1, DNMT3a, and DNMT3b) was recently demonstrated using a CRISPR approach 
in neurons (Swiech et al., 2015). Combined with the high economy of sgRNA production these studies 
pave the way for a combinatorial screening approach in which multiple genes are concurrently 
targeted for knockout. 
Third, future screening projects could take advantage of the precision of CRISPR gene targeting without 
the ensuing DNA disruption. This is because Cas nucleases can be rendered catalytically inactive and 
unable to cleave DNA while still maintaining the ability to bind specific genomic loci under the control 
of user-designed sgRNA. One simple example is the fusion of the transcriptional activation domain 
VP64 to dCas9 to create a tool for targeted upregulation of specific genes (Perez-Pinera et al., 2013). 
The practical applications of targeted gene manipulation are nearly limitless and include the possibility 
of performing simultaneous, combinatorial knockout and overexpression screening. 
Finally, CRISPR-mediated knockout has now been demonstrated to be highly effective in CNS neurons 
in vivo. Although the large size of the spCas9 enzyme can present challenges to viral delivery, strategies 
to circumvent this problem are being developed. For instance, the use of smaller Cas9 family members 
or transgenic animals that conditionally express spCas9 are proving to be effective (Cong et al., 2013, 
Ran et al., 2015). Viral delivery of multiple sgRNA may therefore represent a rapid and flexible 
alternative to current transgenic approaches to achieving simultaneous knockout of multiple genes. 
Moreover, transgenic animals with constitutively expressed Cas9 will likely be useful as a source of 
cells for in vitro screening by simplifying sgRNA delivery and perhaps accelerating the onset of 
knockdown by eliminating the lag between transfection and Cas9 expression. It is clear that axon 
regeneration is regulated by many interacting genes and combinatorial gene manipulations have 
proven most effective in promoting growth (Belin et al., 2015, Jin et al., 2015, Sun et al., 2011). Thus 
the prospect exists that CRISPR-based approaches may accelerate both in vitro discovery of gene 
interactions that regulate axon growth, and the transition to combinatorial testing of lead hits in vivo. 
Overall it is clear that CRISPR-based approaches have enormous potential to expand understanding of 
interactive gene function in a variety of cell types. In this context, the current demonstration of CRISPR 
efficacy and compatibility with high content screening in cultured CNS neurons is a promising indicator 
that this potential can be harnessed for neuroscience research. 
The following are the supplementary data related to this article. 
 
Supplementary Fig. 1. The degree of CRISPR-mediated knockdown of PTEN correlates with EGFP-reporter 
intensity. P3–P5 cortical neurons were co-transfected with EGFP reporter plasmid and plasmid co-expressing 
spCas9 and one of four distinct sgRNA sequences targeting PTEN, or non-targeting sgRNA. At 14 days post-
transfection cells were fixed and immunostained for PTEN and Cellomics automated microscopy quantified 
immunofluorescence and EGFP reporter intensity. Then, the PTEN fluorescence of all cells was binned by EGFP 
intensity to determine the relationship between the fluorescence of the transfection marker and the level of 
PTEN knockdown. In all anti-PTEN sgRNA treatments 10% of cells with the brightest EGFP signal show a large and 
consistent reduction in PTEN fluorescence compared to the non-targeting control treatment (p < 0.001, ANOVA 
with post-hoc Dunnett's). 
 
 Supplementary Fig. 2. CRISPR-mediated decreases in PTEN expression persist following replating at 7DIV. P3-P5 
cortical neurons were transfected with plasmid DNA co-expressing spCas9 and anti-PTEN or non-targeting 
sgRNA, along with plasmid EGFP reporter. (A–D) Show example image of replated cortical neurons. (A) 
Brightfield shows two neurons extending neurites 24 h following replating. (B) EGFP identifies transfection 
(arrow). (C) Immunohistochemistry detects PTEN protein in an EGFP-negative neuron (arrowhead), but not in a 
transfected neighbor (arrow). (D) DAPI staining identifies both objects as nuclei containing cells (E) Each dot 
represents PTEN immunofluorescence intensity in a single transfected (EGFP +) neuron at 7DIV plus 24 h post-
replating. Grey boxes indicate a threshold set by the dimmest 5% of control-transfected neurons, and the 
percent of anti-PTEN cells that fall below that threshold is quantified above. Anti-PTEN sgRNA induces a 
significant reduction in the population average PTEN intensity (p = 2.5 × 10− 13, unpaired t-test), with 75% of cells 
below threshold. N = 40 cells per group. 
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